Champions Oncology
CSBR
46 hedge funds and large institutions have $65.5M invested in Champions Oncology in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
45% more capital inflows, than outflows
Capital inflows: $4.71M | Capital outflows: $3.25M
5% more funds holding
Funds holding: 44 → 46 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.5% less ownership
Funds ownership: 58.16% → 55.66% (-2.5%)
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.24M |
| 2 |
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$585K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$484K |
| 4 |
Zebra Capital Management
Stamford,
Connecticut
|
+$301K |
| 5 |
STRS Ohio
Columbus,
Ohio
|
+$275K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$1.71M |
| 2 |
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$798K |
| 3 |
Essex Investment Management
Boston,
Massachusetts
|
-$230K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$144K |
| 5 |
Overbrook Management Corp
New York
|
-$115K |
CSBR Hedge Fund Activity: Q3 2020 in Review
46 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q3 2020, worth a combined $65.5M — down 0.84% from $66.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CSBR positions and 1 closed out — a net gain of 2 holders — while 12 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.24M. The largest seller was Cadence Capital Management, cutting an estimated $1.71M.
- 46 institutional investors held Champions Oncology (CSBR) as of Q3 2020, up from 44 in Q2 2020.
- Funds reported $65.5M of Champions Oncology stock for Q3 2020, down 0.84% quarter-over-quarter.
- 3 funds opened new Champions Oncology positions in Q3 2020 and 1 closed out, a net change of +2 holders.
- The largest Champions Oncology buyer in Q3 2020 was Vanguard Group, an estimated $2.24M added.
- The largest Champions Oncology seller in Q3 2020 was Cadence Capital Management, an estimated $1.71M sold.
Based on aggregated 13F filings for Q3 2020.